The aim of this study is to clarify the efficacy and safety of neoadjuvant FOLFIRINOX and nab-paclitaxel + gemcitabine for borderline resectable pancreatic cancer.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
50
R0 resection rate
surgery is supposed to be performed 3 months after the initiation of chemotherapy
Time frame: 3 months
completion rate of chemotherapy
chemotherapy is supposed to take 3 months
Time frame: 3 months
relative dose intensity
chemotherapy is supposed to take 3 months
Time frame: 3 months
adverse event
chemotherapy is supposed to take 3 months
Time frame: 3 months
tumor response
tumor response to chemotherapy will be assessed based on Response Evaluation Criteria In Solid Tumor (RECIST). CR: Complete Response, PR: Partial Response, PD: Progression, SD: Stable Disease, NE: Not Evaluable
Time frame: 3 months
disease free survival
Time frame: 3 years after the surgery
overall survival
Time frame: 3 years after the surgery
surgical complication
Time frame: 1 month after the surgery
quality of the tumor
Chemotherapy is supposed to take 3 months. After the completion of chemotherapy, the quality of the tumor will be assessed by imaging findings, such as CT number and Standardized uptake value.
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.